BRAF and colorectal carcinoma: CRC patients with BRAF V600E mutations exhibit poor prognosis and response to conventional cytotoxic chemotherapy (FOLFOX)/(FOLFIRI) or novel target chemotherapy, such as panitumumab and cetuximab, monoclonal antibodies targeting the epidermal growth factor receptor (EGFR/ERBB1) (30).